Most Read Articles
Yesterday
Administering intranasal desmopressin to patients with renal dysfunction not requiring haemodialysis reduces bleeding complications during renal biopsies, especially minor complications such as perinephric haematomas, a study has found. However, it may increase the risk of incident hyponatraemia.
Pearl Toh, 10 Oct 2019
Adding a LAMA* to the double combination therapy of ICS** plus LABA*** in a single inhaler improves lung function and reduces exacerbations in patients whose asthma is inadequately controlled with the combination treatment, according to the TRIMARAN and TRIGGER# studies presented at ERS 2019.
3 days ago
Environmental quality and exposure to pollution may play a small part in the development of metabolic diseases, such as diabetes, a new study has found.
Tristan Manalac, 5 days ago
Sleep deprivation impairs adolescents’ long-term retention of classroom material, according to a recent Singapore study.

Advanced CKD stage a risk factor for discontinuation of ACE inhibitors, ARBs

23 May 2019

Patients at a more advanced stage of chronic kidney disease (CKD) are highly likely to discontinue treatment with commonly used blood pressure (BP)-lowering drugs, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), a study has found.

Researchers used data from the Geisinger Health System (2004–2015) and identified 54,588 ACE inhibitor/ARB users with a baseline estimated glomerular filtration rate (eGFR) of ≥15 mL/min/1.73 m2. None of the patients had previous diagnosis of end-stage renal disease.

Time to treatment discontinuation, defined as a therapy gap of ≥60 days, was evaluated in relation to CKD stage (ie, G1, G2, G3a, G3b and G4) using Kaplan Meier curves and multivariable Cox proportional hazards models.

Results showed that the risk of discontinuation increased with advancing CKD stage. The hazard ratios (HRs) relative to CKD stage G1 were 1.06 (95 percent CI, 1.03–1.09) with stage G2, 1.24 (1.19–1.30) with stage G3a, 1.49 (1.40–1.59) with stage G3b and 2.31 (2.09–2.57) with stage G4. Estimates were higher when G-stage was treated as time-dependent.

On further analysis, risk of discontinuation was higher in 2008–2011 (HR, 1.16; 1.13–1.19) and 2012–2015 (HR, 1.28; 1.24–1.32) than in 2004–2007. Hospitalizations associated with or not related to acute kidney infection both contributed to increased risk of discontinuation (HR, 17.34; 16.01–18.78 and HR, 4.11; 3.94–4.30, respectively).

Of the 29,029 ACE inhibitor/ARB users who discontinued, 6,187 (21.3 percent) restarted therapy within 6 months of discontinuation.

The findings indicate that more advanced CKD stage is a risk factor for ACE inhibitor/ARB discontinuation, with a trend toward greater discontinuation in more recent years, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Yesterday
Administering intranasal desmopressin to patients with renal dysfunction not requiring haemodialysis reduces bleeding complications during renal biopsies, especially minor complications such as perinephric haematomas, a study has found. However, it may increase the risk of incident hyponatraemia.
Pearl Toh, 10 Oct 2019
Adding a LAMA* to the double combination therapy of ICS** plus LABA*** in a single inhaler improves lung function and reduces exacerbations in patients whose asthma is inadequately controlled with the combination treatment, according to the TRIMARAN and TRIGGER# studies presented at ERS 2019.
3 days ago
Environmental quality and exposure to pollution may play a small part in the development of metabolic diseases, such as diabetes, a new study has found.
Tristan Manalac, 5 days ago
Sleep deprivation impairs adolescents’ long-term retention of classroom material, according to a recent Singapore study.